A Phase 1, Single- and Multiple-Dose Safety and Pharmacokinetic Study of Oral and IV Tedizolid Phosphate (MK-1986) in Inpatients Under 2 Years Old
Latest Information Update: 25 Jul 2024
At a glance
- Drugs Tedizolid (Primary) ; Tedizolid (Primary)
- Indications Gram-positive infections
- Focus Pharmacokinetics
- Sponsors Merck Sharp & Dohme
- 31 May 2023 This trial has been completed in Bulgaria, according to European Clinical Trials Database record.
- 10 Apr 2023 Status changed from active, no longer recruiting to completed.
- 30 Mar 2023 Planned End Date changed from 28 Jun 2024 to 6 Apr 2023.